trending Market Intelligence /marketintelligence/en/news-insights/trending/lgc9mVvdCj5t6vnsgoyrCg2 content esgSubNav
In This List

Australian drug development company Phylogica rebrands to PYC Therapeutics

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Australian drug development company Phylogica rebrands to PYC Therapeutics

Phylogica Ltd. changed its name to PYC Therapeutics Ltd. to reflect the company's shifted focus from drug discovery to drug development.

The name change will come into effect after the company gets shareholder approval at its annual general meeting scheduled for later in the year.

The Perth, Australia-based company has registered the new trading name with the Australian Securities and Investments Commission. It has also submitted a trademark application to IP Australia regarding the new name.

The rebranding is in line with the latest changes in the company's executive board and scientific board.

Phylogica is developing a pipeline of therapies for blinding eye diseases using its proprietary technology.